Ammonul Medicis - Treatment for Urea Cycle Disorder
Ammonul is a combination of 10% sodium phenylacetate and 10% sodium benzoate indicated as an adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.Posted: February 2005
Ammonul (sodium benzoate and sodium phenylacetate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
